scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1113049507 |
P356 | DOI | 10.1186/S12967-019-1847-X |
P932 | PMC publication ID | 6437908 |
P698 | PubMed publication ID | 30917841 |
P50 | author | Patrizia Vici | Q28833492 |
Paolo Marchetti | Q56815155 | ||
Raffaele Giusti | Q89096158 | ||
P2093 | author name string | Lidia Strigari | |
Bruna Cerbelli | |||
Marco Mazzotta | |||
Laura Pizzuti | |||
Andrea Botticelli | |||
Massimiliano Salati | |||
Michela Roberto | |||
Marianna Nuti | |||
Federica Mazzuca | |||
Francesca Romana Di Pietro | |||
Ilaria Grazia Zizzari | |||
P2860 | cites work | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 |
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
Hepatic T cells and liver tolerance | Q35038298 | ||
Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer | Q38761172 | ||
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. | Q46573013 | ||
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer | Q47101079 | ||
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data | Q47287282 | ||
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. | Q47840963 | ||
Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases | Q50161502 | ||
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. | Q52586557 | ||
Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution. | Q54962510 | ||
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial. | Q55400478 | ||
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57051777 | ||
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? | Q58799410 | ||
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC | Q88973544 | ||
Review of checkpoint immunotherapy for the management of non-small cell lung cancer | Q90931697 | ||
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade | Q91392607 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | nomogram | Q721129 |
immunotherapy | Q1427096 | ||
nivolumab | Q7041828 | ||
P304 | page(s) | 99 | |
P577 | publication date | 2019-03-27 | |
P1433 | published in | Journal of Translational Medicine | Q15716664 |
P1476 | title | A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab | |
P478 | volume | 17 |
Search more.